
Inform Genomics develops personalized medicine products for cancer and inflammatory diseases, leveraging genomic studies to predict patient outcomes.
Inform Genomics, a private company, was founded with the mission to revolutionize personalized medicine for cancer supportive care and inflammatory diseases. They focus on developing innovative diagnostic products that utilize genome-wide association studies and proprietary analytic methods. Their primary offerings are single-source laboratory tests based on SNP clusters, designed to predict individual patient outcomes to various treatments. This approach aims to enhance personalized patient care and improve clinical outcomes.
Notable figures associated with Inform Genomics include experts in genomics and personalized medicine, although specific names are not publicly highlighted. The company has attracted significant interest from investors in the biotech sector due to its pioneering approach. Key achievements include the successful development of their proprietary genomic analysis platform and the launch of their initial diagnostic tests. Inform Genomics' impact lies in its potential to transform patient care by providing tailored treatment strategies based on genetic profiles, thereby improving the efficacy of medical interventions.
Companies similar to Inform Genomics include Foundation Medicine, Personal Genome Diagnostics, Genome Insight and EcoGenome.
Inform Genomics was founded in 2010.
Inform Genomics' headquarters is located in Boston, MA, US.
Inform Genomics' most recent funding round was for $1.7M (USD) in February 2014.
As of Feb 11, 2014, Inform Genomics has raised a total of $3.1M (USD).
Inform Genomics has 30 employees as of Feb 5, 2024.
Genome Insight